Satellos Bioscience (DE:0IT)
FRANKFURT:0IT
0IT Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0IT Stock 12 Month Forecast
Average Price Target
€18.88
▲(158.59% Upside)
| Highest Price Target€35.16 | Average Price Target€18.88 | Lowest Price Target€9.67 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
€11.76
Buy
61.04%
Upside
Initiated
05/21/26
Guggenheim
€20.22
Buy
176.96%
Upside
Reiterated
05/19/26
H.C. Wainwright
€9.67
Buy
32.46%
Upside
Reiterated
05/18/26
Oppenheimer
€35.16
Buy
381.67%
Upside
Reiterated
04/20/26
Leerink Partners
€17.58
Buy
140.84%
Upside
Initiated
04/06/26
Leede Financial
€14.06
Buy
92.67%
Upside
Reiterated
03/11/26
The Canadian biotech stock will beat the market, analyst saysLoe said the Ontario-based rare-disease drug developer recently reported updated interim Phase II data from its TRAILHEAD trial, a 30-patient adult DMD study evaluating SAT-3247, an orally active small-molecule drug designed to inhibit adaptor-associated protein kinase 1 (AAK1).
Cantor Fitzgerald
―
Buy
―
Initiated
03/11/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
€11.76
Buy
61.04%
Upside
Initiated
05/21/26
Guggenheim
€20.22
Buy
176.96%
Upside
Reiterated
05/19/26
H.C. Wainwright
€9.67
Buy
32.46%
Upside
Reiterated
05/18/26
Oppenheimer
€35.16
Buy
381.67%
Upside
Reiterated
04/20/26
Leerink Partners
€17.58
Buy
140.84%
Upside
Initiated
04/06/26
Leede Financial
€14.06
Buy
92.67%
Upside
Reiterated
03/11/26
The Canadian biotech stock will beat the market, analyst saysLoe said the Ontario-based rare-disease drug developer recently reported updated interim Phase II data from its TRAILHEAD trial, a 30-patient adult DMD study evaluating SAT-3247, an orally active small-molecule drug designed to inhibit adaptor-associated protein kinase 1 (AAK1).
Cantor Fitzgerald
―
Buy
―
Initiated
03/11/26
Best Analysts Covering Satellos Bioscience
3 Months
Success Rate
7/12 ratings generated profit
Average Return
+20.64%
Copying Arthur He CFA's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +20.64% per trade.
1 Year
Success Rate
7/12 ratings generated profit
Average Return
+7.21%
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +7.21% per trade.
2 Years
Success Rate
7/12 ratings generated profit
Average Return
+9.52%
Copying Arthur He CFA's trades and holding each position for 2 Years would result in 58.33% of your transactions generating a profit, with an average return of +9.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0IT Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
4
6
8
6
Buy
1
2
2
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
6
8
9
6
Each month's total comprises the sum of three months' worth of ratings.
0IT Financial Forecast
0IT Stock Forecast FAQ
What is DE:0IT’s average 12-month price target, according to analysts?
Based on analyst ratings, Satellos Bioscience’s 12-month average price target is 18.88.
What is DE:0IT’s upside potential, based on the analysts’ average price target?
Satellos Bioscience has 158.59% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Satellos Bioscience a Buy, Sell or Hold?
Satellos Bioscience has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Satellos Bioscience’s share price target?
The average share price target for Satellos Bioscience is 18.88. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €35.16 ,and the lowest forecast is €9.67. The average share price target represents 158.59% Increase from the current price of €7.3.
The highest analyst share price target is €35.16 ,and the lowest forecast is €9.67. The average share price target represents 158.59% Increase from the current price of €7.3.
What do analysts say about Satellos Bioscience?
Satellos Bioscience’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of Satellos Bioscience?
To buy shares of DE:0IT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.